The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMedium•27 March 2026•

1 min read

Eli Lilly Reports Positive 4-Year Data for Eczema Drug EBGLYSS

Key Facts

1Data from the ADlong study showed EBGLYSS delivered durable disease control for up to four years in patients with atopic dermatitis.

275% of patients achieved near-complete skin clearance (EASI-90) and 78% experienced significant itch relief.

380% of patients maintained results without the need for topical corticosteroids.

Eli Lilly and Company (LLY) released long-term Phase 3b data from its ADlong study, demonstrating that EBGLYSS maintains efficacy for up to four years. The study revealed that 75% of patients with moderate-to-severe atopic dermatitis achieved near-complete skin clearance, measured by EASI-90. Furthermore, 78% of participants experienced significant itch relief, underscoring the drug's potential as a durable long-term treatment option. Notably, 80% of patients were able to maintain these clinical results without the supplemental use of topical corticosteroids. The data, presented at the American Academy of Dermatology (AAD) Annual Meeting, strengthens Eli Lilly's competitive position in the immunology sector. These findings provide a robust clinical foundation for EBGLYSS as it competes against established treatments like Sanofi's Dupixent in the global market.

Create Free Account